Clinical Trial Update: A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating safety, tolerability, and pharmacokinetics of MNKD-201 in idiopathic pulmonary fibrosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• MNKD-201

Snippet

Sponsor: Mannkind Corporation | Conditions: Idiopathic Pulmonary Fibrosis (IPF) | Phase 1 | Status: RECRUITING